These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11923638)

  • 41. Distribution of gadomelitol in a human breast tumor model in mice.
    Corot C; Robert P; Lancelot E; Martinell A; Santus R
    MAGMA; 2005 Jul; 18(3):138-43. PubMed ID: 16047191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the tumoral biodistribution of P792, a rapid clearance blood pool agent and Gd-DOTA in a C6 glioma cerebral tumor model in rats.
    Robert P; Santus R; Violas X; Rémy C; Corot C
    Acad Radiol; 2002 Aug; 9 Suppl 2():S521-4. PubMed ID: 12188327
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacokinetics and Tolerability of the Cancer-Targeting MRI Contrast Agent MT218 in Healthy Males.
    Li Y; Apseloff G; Tweedle MF; Gao S; Henry E; Lu ZR
    Invest Radiol; 2024 Feb; 59(2):165-169. PubMed ID: 38015107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
    Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
    Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
    DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
    [No Abstract]   [Full Text] [Related]  

  • 46. P760 and P775: MRI contrast agents characterized by new pharmacokinetic properties.
    Port M; Meyer D; Bonnemain B; Corot C; Schaefer M; Rousseaux O; Simonot C; Bourrinet P; Benderbous S; Dencausse A; Devoldere L
    MAGMA; 1999 Aug; 8(3):172-6. PubMed ID: 10504044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arterial concentration profiles of two blood pool agents and Gd-DOTA after intravenous injection in rabbits.
    Corot CA; Violas X; Robert P; Port M
    Acad Radiol; 2002 May; 9 Suppl 1():S137-9. PubMed ID: 12019850
    [No Abstract]   [Full Text] [Related]  

  • 48. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model.
    Ceelen W; Smeets P; Backes W; Van Damme N; Boterberg T; Demetter P; Bouckenooghe I; De Visschere M; Peeters M; Pattyn P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1188-96. PubMed ID: 16457965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
    Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
    Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of MR contrast media.
    Olukotun AY
    Radiology; 1994 May; 191(2):584-5. PubMed ID: 8153348
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure.
    Tombach B; Bremer C; Reimer P; Schaefer RM; Ebert W; Geens V; Heindel W
    Invest Radiol; 2000 Jan; 35(1):35-40. PubMed ID: 10639034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety assessment of gadoversetamide (OptiMARK) administered by power injector.
    Abdou N; Napoli AM; Hynes MR; Allen JC; Wible JH
    J Magn Reson Imaging; 2004 Jan; 19(1):133-40. PubMed ID: 14696230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gadolinium Chelate Safety in Pregnancy: Barely Detectable Gadolinium Levels in the Juvenile Nonhuman Primate after in Utero Exposure.
    Prola-Netto J; Woods M; Roberts VHJ; Sullivan EL; Miller CA; Frias AE; Oh KY
    Radiology; 2018 Jan; 286(1):122-128. PubMed ID: 28873045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.
    Shamsi K; Yucel EK; Chamberlin P
    Invest Radiol; 2006 Nov; 41(11):822-30. PubMed ID: 17035873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease.
    Bokor D; Chambers JB; Rees PJ; Mant TG; Luzzani F; Spinazzi A
    Invest Radiol; 2001 Feb; 36(2):104-9. PubMed ID: 11224758
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
    Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
    J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transvascular and interstitial transport in rat hepatocellular carcinomas: dynamic contrast-enhanced MRI assessment with low- and high-molecular weight agents.
    Michoux N; Huwart L; Abarca-Quinones J; Dorvillius M; Annet L; Peeters F; Van Beers BE
    J Magn Reson Imaging; 2008 Oct; 28(4):906-14. PubMed ID: 18821616
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent.
    Van Wagoner M; Worah D
    Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI.
    Jia G; Heverhagen JT; Henry H; Polzer H; Baudendistel KT; von Tengg-Kobligk H; Levine AL; Rosol TJ; Knopp MV
    Magn Reson Imaging; 2006 Jul; 24(6):721-5. PubMed ID: 16824967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.